As President Trump readies to implement a new wave of tariffs, the pharmaceutical sector braces for potential challenges ahead. Industry leaders are closely monitoring this development as drugs may become a key target in the tariff strategy. Ashleigh Furlong from Bloomberg reports on how this could influence pricing and availability within the industry.